Babylon Capital has highlighted Inmode (NASDAQ:INMD), a medical technology company, as an undervalued high-quality business with long-term potential. The company has a strong balance sheet, impressive growth, and high return metrics. Despite being a young mid-cap business, it has the potential to significantly impact the value of a portfolio, especially if it gains approvals for the use of its technology in non-aesthetic applications.